Oculus Technologies of Mexico
introduced Microcyn® during
the 2003 gathering of the Mexican Association of General
Surgeons.
Diabetic
foot ulcers treated with Microcyn® Technology
as part of a comprehensive treatment regimen have
shown not only elimination of fetid odor, but also
important clinical benefits with respect to the reduction
of cellulitis and tissue toxicity (cytotoxicity)
when compared to patients treated with conventional
therapy alone. Patients that in the past might have
had to undergo radical procedures such as amputation,
are now being healed and their limbs saved.
In 300 patient studies conducted in Europe
using Microcyn® Technology
in a comprehensive treatment program the following results
were reported:
Patients
treated with Microcyn® Technology
showed an important clinical benefit with respect to
the reduction of fetid odor. All patients showed a
reduction in fetid odor compared to the control patients.
Microcyn® Technology
patients achieved a significant reduction of cellulitis
compared to of the control patients.
Patients
in the Microcyn® Technology
intervention group showed improved outcome of the wound
(infection to granulation tissue development) compared
to the control patients.
Microcyn® Technology
patients had improved tissue and skin around the wound
compared to control patients.
